Silicon dioxide vaginal gel and short‐term high‐risk human papillomavirus DNA detectability: A randomized controlled trial
- 1Department of Obstetrics and Gynecology, Marien Hospital Herne Klinikum der Ruhr‐Universität Bochum Herne Germany
Abstract
Introduction: Intravaginal products, including silicon dioxide‐based gels, are marketed to support short‐term high‐risk human papillomavirus (hrHPV) clearance or loss of detectability, but independent randomized evidence testing these short‐term claims against observation is limited. We evaluated whether daily intravaginal silicon dioxide‐based gel treatment increases the proportion of women with no detectable cervical hrHPV DNA compared with observation alone.
Material and Methods: This prospective, single‐center, parallel‐group, randomized, open‐label controlled trial included women with PCR‐confirmed cervical hrHPV infection and no indication for immediate treatment. Participants were randomized 1:1 to 3 months of self‐administered daily intravaginal gel treatment or observation alone. The primary outcome was absence of detectable cervical hrHPV DNA by PCR at 3 months. Secondary outcomes during the randomized study period were patient‐reported satisfaction and adverse events. Trial registration: ClinicalTrials.gov, NCT05509413, https://clinicaltrials.gov/study/NCT05509413.
Results: Between November 2022 and January 2025, 242 women were randomized, with 121 allocated to each group. Primary‐endpoint data were available for 208 women. At 3 months, hrHPV DNA was not detected in 18/99 women (18%) in the gel treatment group and 23/109 women (21%) in the observation group (absolute risk difference −2.9 percentage points, 95% CI −14 to 8; p = 0.60). A reduced post hoc adjusted sensitivity analysis did not materially change the interpretation of the primary comparison. Patient‐reported adverse events were more frequent in the gel treatment group than in the observation group (32/99 [32%] vs. 2/106 [2%]; absolute risk difference 30 percentage points, 95% CI 21 to 40; p < 0.001). Satisfaction scores were high in both groups but lower with gel treatment.
Conclusions: In this randomized trial, 3 months of daily intravaginal silicon dioxide‐based gel treatment did not improve short‐term loss of detectable cervical hrHPV DNA compared with observation alone. The trial did not reproduce the large short‐term virologic benefit suggested by prior product‐related studies. The findings do not support routine use of this intervention solely to promote short‐term hrHPV non‐detectability in women without an indication for immediate treatment, particularly given the higher frequency of local adverse events.
Related
- Personalized assistive EMG-controlled virtual reality interface combined with cerebellar-iTBS for post-stroke arm recovery (ERICA): study protocol for a three-arm randomized controlled trial
- Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial
- Simulation-based education improves postpartum hemorrhage management knowledge and skills: a randomized controlled trial
- Omitting the Eradication Phase of Treatment of Adults with Melioidosis: A Pilot, Single-Center Randomized Controlled Trial
- A double-blind randomized controlled trial comparing intranasal dexmedetomidine with and without fentanyl for pediatric premedication
BibTeX
@article{hecken2026silicon,
title = {{Silicon dioxide vaginal gel and short‐term high‐risk human papillomavirus DNA detectability: A randomized controlled trial}},
author = {Julia M. Hecken and Clemens B. Tempfer and Katrin Klaus and Jan Scheich and Günther A. Rezniczek},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
month = aug,
doi = {10.1111/aogs.70332},
url = {https://doi.org/10.1111/aogs.70332},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Silicon dioxide vaginal gel and short‐term high‐risk human papillomavirus DNA detectability: A randomized controlled trial
AU - Julia M. Hecken
AU - Clemens B. Tempfer
AU - Katrin Klaus
AU - Jan Scheich
AU - Günther A. Rezniczek
PY - 2026
DA - 2026/08/05
JO - Acta Obstetricia et Gynecologica Scandinavica
DO - 10.1111/aogs.70332
UR - https://doi.org/10.1111/aogs.70332
AB - Introduction: Intravaginal products, including silicon dioxide‐based gels, are marketed to support short‐term high‐risk human papillomavirus (hrHPV) clearance or loss of detectability, but independent randomized evidence testing these short‐term claims against observation is limited. We evaluated whether daily intravaginal silicon dioxide‐based gel treatment increases the proportion of women with no detectable cervical hrHPV DNA compared with observation alone. Material and Methods: This prospective, single‐center, parallel‐group, randomized, open‐label controlled trial included women with PCR‐confirmed cervical hrHPV infection and no indication for immediate treatment. Participants were randomized 1:1 to 3 months of self‐administered daily intravaginal gel treatment or observation alone. The primary outcome was absence of detectable cervical hrHPV DNA by PCR at 3 months. Secondary outcomes during the randomized study period were patient‐reported satisfaction and adverse events. Trial registration: ClinicalTrials.gov, NCT05509413, https://clinicaltrials.gov/study/NCT05509413. Results: Between November 2022 and January 2025, 242 women were randomized, with 121 allocated to each group. Primary‐endpoint data were available for 208 women. At 3 months, hrHPV DNA was not detected in 18/99 women (18%) in the gel treatment group and 23/109 women (21%) in the observation group (absolute risk difference −2.9 percentage points, 95% CI −14 to 8; p = 0.60). A reduced post hoc adjusted sensitivity analysis did not materially change the interpretation of the primary comparison. Patient‐reported adverse events were more frequent in the gel treatment group than in the observation group (32/99 [32%] vs. 2/106 [2%]; absolute risk difference 30 percentage points, 95% CI 21 to 40; p < 0.001). Satisfaction scores were high in both groups but lower with gel treatment. Conclusions: In this randomized trial, 3 months of daily intravaginal silicon dioxide‐based gel treatment did not improve short‐term loss of detectable cervical hrHPV DNA compared with observation alone. The trial did not reproduce the large short‐term virologic benefit suggested by prior product‐related studies. The findings do not support routine use of this intervention solely to promote short‐term hrHPV non‐detectability in women without an indication for immediate treatment, particularly given the higher frequency of local adverse events.
SN - 0001-6349
SN - 1600-0412
ER -